4.7 Article

Prospective Validation of the 0/1-h Algorithm for Early Diagnosis of Myocardial Infarction

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 72, Issue 6, Pages 620-632

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2018.05.040

Keywords

diagnosis of myocardial infarction; diagnostic algorithms; myocardial infarction; rule-in; rule-out; troponin

Funding

  1. Swiss National Science Foundation
  2. Swiss Heart Foundation
  3. KTI
  4. European Union
  5. Stiftung fur kardiovaskulare Forschung Basel
  6. Abbott
  7. Beckman Coulter
  8. Biomerieux
  9. Brahms
  10. Roche
  11. Siemens
  12. Singulex
  13. German Center of Cardiovascular Research
  14. Abbott Diagnostics
  15. Swiss National Science Foundation [P300PB_167803, PASMP3-136995]
  16. University Hospital of Basel
  17. University of Basel
  18. Cardiovascular Research Foundation Basel
  19. German Heart Foundation/German Foundation of Heart Research
  20. Else Kroner Fresenius Stiftung
  21. FAG Basel
  22. Gottfried and Julia Bangerter-Rhyner Foundation
  23. Goldschmidt-Jacobson-Foundation
  24. Professor Max Cloetta Foundation
  25. Uniscientia Foundation Vaduz
  26. Department of Internal Medicine, University Hospital Basel
  27. Bayer
  28. Boehringer Ingelheim
  29. Thermo Fisher
  30. Alere
  31. AstraZeneca
  32. Sphingotec
  33. Swiss National Science Foundation (SNF) [P300PB_167803] Funding Source: Swiss National Science Foundation (SNF)

Ask authors/readers for more resources

BACKGROUND The safety of the European Society of Cardiology (ESC) 0/1-h algorithm for rapid rule-out and rule-in of non-ST-segment elevation myocardial infarction (NSTEMI) using high-sensitivity cardiac troponin (hs-cTn) has been questioned. OBJECTIVES This study aimed to validate the diagnostic performance of the 0/1-h algorithm in a large multicenter study. METHODS The authors prospectively enrolled unsetected patients in 6 countries presenting to the emergency department with symptoms suggestive of NSTEMI. Final diagnosis was centrally adjudicated by 2 independent cardiologists. Hs-cTnT and hs-cTnI blood concentrations were measured at presentation and after 1 h. Safety of rule-out was quantified by the negative predictive value (NPV) for NSTEMI, accuracy of rule-in by the positive predictive value (PPV), and overall efficacy by the proportion of patients triaged towards rule-out or rule-in within 1 h. RESULTS Prevalence of NSTEMI was 17%. Among 4,368 patients with serial hs-cTnT measurements available, safety of rule-out (NPV 99.8%, 2,488 of 2,493), accuracy of rule-in (PPV 74.5%, 572 of 768), and overall efficacy were high by assigning three-fourths of patients either to rule-out (57%, 2,493 to 4,368) or rule-in (18%, 768 to 4,368). Similarly, among 3,500 patients with serial hs-cTnI measurements, safety of rule-out (NPV 99.7%, 1,528 of 1,533), accuracy of rule-in (PPV 62.3%, 498 of 800), and overall efficacy were high by assigning more than two-thirds of patients either to rule-out (44%, 1,533 of 3,500) or rule-in (23%, 800 of 3,500). Excellent safety was confirmed in multiple subgroup analyses including patients presenting early h) after chest pain onset. CONCLUSIONS The ESC 0/1-h algorithm using hs-cTnT and hs-cTnI is very safe and effective in triaging patients with suspected NSTEMI. (C) 2018 by the American College of Cardiology Foundation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available